Arkolith/Insider Trading/KYTX/Form 4

Bain Capital Life Sciences Fund III, L.P.

10% OwnerKyverna Therapeutics, Inc. (KYTX) · full profile →Form 4 · filed Feb 14, 2024
Net Buying
Open-Market Buys
$9.9M
Open-Market Sells
$0
Net Open-Market Flow
$9.9M
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 12, 2024Conversion(C)2.7M——2.7M
Feb 12, 2024Buy(P)450K$22.00$9.9M3.2M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 12, 2024Conversion(C)12.4M—$00

Transaction Codes

C
Conversion of a derivative
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-015358) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML